Update on the therapeutic potential of PDE4 inhibitors

Expert Opinion on Investigational Drugs

Volumn 11, Issue 1, 2002, Pages 1-13

  Dyke, H J ^a   Montana, J G ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Anti inflammatory; Asthma; Cilomilast; COPD; IBD; MS; PDE4; Psoriasis; RA; Rolipram; TNF

Indexed keywords

1 BUTYL 3 PROPYLXANTHINE; 3 (3 CYCLOPENTYLOXY 4 METHOXYBENZYL) 6 ETHYLAMINO 8 ISOPROPYL 3H PURINE; 4 (3 CHLOROPHENYL) 1,7 DIETHYLPYRIDO[2,3 D]PYRIMIDIN 2(1H) ONE; 4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; AROFYLLINE; BAY 19 8004; CDC 801; CDC 806; CDC 998; CI 1018; CILOMILAST; CIPAMFYLLINE; CYCLIC AMP; CYCLIC GMP; DIGITOXIN; IC 485; KW 4490; L 791943; MESOPRAM; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; PD 189659; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PICLAMILAST; PUMAFENTRINE; ROFLUMILAST; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 11294 A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG UTILIZATION; ENZYME INACTIVATION; EOSINOPHIL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY DISEASE; MALE; MOUSE; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; RAT; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; HUMANS; INFLAMMATORY BOWEL DISEASES; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PHOSPHODIESTERASE INHIBITORS; SKIN DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036139840     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.1.1     Document Type: Review

References (98)

1. Phosphorylation-dephosphorylation of enzymes
2. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
3. Recent progress in understanding the hormonal regulation of phosphodiesterases
4. Diversity in cyclic nucleotide isoenzyme families
5. Cyclic nucleotide phosphodiesterases: Relating structure and function
6. PDE4 inhibitors: Sustained patenting activity as leading drugs near the market
7. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents
8. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) Type 4 inhibitors
9. The therapeutic potential of PDE4 inhibitors
10. PDE4 inhibitors - A review of the recent patent literature
11. Phosphodiesterase 4 inhibitors
12. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies
13. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
14. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease
15. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
16. PDE4 inhibitors and chronic obstructive pulmonary disease
17. The potential of PDE4 inhibitors in asthma or COPD
18. Chronic Lipopolysaccharide exposure on airway function, cell infiltration, and nitric oxide generation in conscious guinea pigs: Effect of rolipram and dexamethasone
19. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro
20. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
21. Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: Novel PDE4 inhibitors
22. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7 tetrahydro[1,4]diazepino[6,7,1-hi]indoles: Discovery of potent, selective phosphodiesterase Type 4 inhibitors
23. The profile of SCH351591, a novel phosphodiesterase 4 inhibitor
24. The profile of SCH351591, a novel phosphodiesterase 4 inhibitor
25. A novel phosphodiesterase Type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity
26. Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs
27. Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice, and ferrets
28. Phenyl substituted analogues of CDP-840 as phosphodiesterase-4 inhibitors with improved potency, oral activity and metabolic stability
29. Substituted 4-(2,2-diphenylethyl)-pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters
30. Substituted 4-(2,2-diphenylethyl)-pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters
31. Substituted 4-(2,2-diphenylethyl)-pyridine-N-oxides as potent and selective phosphodiesterase-4 inhibitors
32. Comparison of PDE 4 inhibitors, rolipram and SB207499 (Ariflo™), in a rat model of pulmonary neutrophilia
33. N-arylrolipram derivatives as potent and selective PDE4 inhibitors
34. Phthalazine PDE4 inhibitors. Part 2: The synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives
35. Synthesis and biological evaluation of 2,5-dihydropyrazolo[4,3-c]quinolin-3-ones, a novel series of PDE4 inhibitors with low emetic potential and antiasthmatic properties
36. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia
37. Bronchodilator activity of LAS31025, a new selective phoisphodiesterase IV inhibitor
38. A 6-week double-blind, randomised, parallel, placebo-controlled clinical trial to assess efficacy and safety of LAS 31025 in asthmatic patients
39. An overview of the pharmacokinetics of cilomilast (Ariflo), a new, orally active phosphodiesterase 4 inhibitor, in healthy young and elderly volunteers
40. The safety and tolerability of Ariflo TM (SB 207499), a novel and selective phosphodiesterase 4 inhibitor, in healthy male volunteers
41. Safety of Ariflo in a 12 month study of patients with asthma
42. Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast
43. Ariflo, a novel and selective oral PDE4 inhibitor, has a favourable metabolic profile with low potential for drug-drug interactions
44. Ariflo™ improves pulmonary function in patients with asthma: Results of a study in patients taking inhaled corticosteroids
45. SB 207499 improves pulmonary function in patients with asthma receiving concomitant inhaled corticosteroids
46. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study
47. Cilomilast: Pharmacokinetic and pharmacodynamic interactions with digoxin
48. Ariflo efficacy in a 12-month study of patients with asthma
49. Cilomilast (Ariflo) a potent, selective phosphodiesterase 4 inhibitor, reduces exacerbations in COPD patients: Results of a 6 month trial
50. Cilomilast (Ariflo), a potent, selective inhibitor of phosphodiesterase 4, improves lung function in patients with COPD: Results of a 6-month trial
51. Cilomilast (Ariflo) improves health status in patients with COPD: Results of a 6 month trial
52. Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease
53. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose
54. Oral administration of the phosphodiesterase (PDE)4 inhibitor, V11294A inhibits ex vivo agonist-induced cell activation
55. Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE) 4 inhibitor, V1129A, in human volunteers
56. PDE Inhibitors
57. 4396. IDdb Drug Report
58. New drugs in R & D pipeline
59. New drugs in the R&D pipeline
60. Annual Report and Accounts
61. Curative effects of phosphodiesterase 4 inhibitors in dextran sulfate sodium-induced colitis in the rat
62. Selective inhibition of phosphodiesterase Type IV ameliorates chronic colitis and prevents intestinal fibrosis
63. Specific Type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice
64. Dextran sulfate sodium-induced colonic histopathology, but not altered epithgelial ion transport, is reduced by inhibition of phosphodiesterase activity
65. TNF-alpha inhibitors and rheumatoid arthritis
66. Effects of the phosphodiesterase 4 inhibitor RPR 73401 in a model of immunological inflammation
67. Effects of SB 207499 in a model of allergic dermatitis
68. Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis
69. Influence of food on the pharmacokinetics of BRL-61063 in healthy subjects
70. IDdb Drug Report
71. Potential of phosphodiesterase Type IV inhibitors in the treatment of reumatoid arthritis
72. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis
73. Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats
74. Efficacy of a novel PDE-IV inhibitor in murine collagen-induced arthritis
75. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors
76. Benzofuran based PDE4 inhibitors
77. Orally active indole N-oxide PDE4 inhibitors
78. 2-Substituted-4-methoxybenzimidazole-based PDD4 inhibitors
79. Phosphodiesterase Type 4 inhibitors potential in the treatment of multiple sclerosis?
80. The Type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents
81. Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models
82. Potential of PDE4 inhibitors in the treatment of osteopenia
83. Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice
84. Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
85. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis
86. Chronic Type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine
87. Suppression of experimental systemic lupus erthematosus (SLE) in mice via TNF inhibition by an anti-TNFα monoclonal antibody and by pentoxiphylline
88. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism
89. Inhibitions des contractions uterines: Nouvelles approaches pharmacologigues in vitro sur le myometre human gravide